Clinical Trial Update: A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation [Phase 2]

View source ↗

Summary

Pfizer-sponsored Phase 2 trial evaluating the safety of apixaban (Eliquis) in patients with atrial fibrillation has completed and results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Eliquis (apixaban)

Snippet

Sponsor: Pfizer | Conditions: Atrial Fibrillation | Phase 2 | Status: COMPLETED | Results posted: 2013-03-06